Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Fresh from the biotech pipeline: too much, too fast?

Nature Biotechnology volume 40, pages 155–162 (2022)Cite this article

2021 witnessed regulators’ continued push to accelerate approvals and adjust to COVID-19, but has the pendulum swung too far in drug makers’ favor?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Historical FDA approvals.
Fig. 2: 2021 FDA approvals by disease group.
Fig. 3: Drug approvals with expedited reviews in 2021.

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Fresh from the biotech pipeline: too much, too fast?. Nat Biotechnol 40, 155–162 (2022). https://doi.org/10.1038/s41587-022-01208-2

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-022-01208-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing